Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial focused on improving how cystic fibrosis patients are prioritized on the lung transplant waitlist using something called the Lung Allocation Score — can you explain how my own LAS is currently calculated and whether the tools tested in this study might affect how my score is managed?
2. 2Since this trial has already been completed, have the clinical tools or decision-support strategies it tested been adopted here, and could they change how my transplant team monitors me while I'm waiting?
3. 3The study was specifically looking at reducing deaths while patients are still on the transplant waitlist — what does my current risk look like while waiting, and is my care team using any updated protocols that came out of research like this?
4. 4This trial was categorized as 'not applicable' for phase, meaning it was testing a clinical process rather than a drug or device — does that mean the findings are more or less likely to be used in my care right now compared to a traditional drug trial?
5. 5Given that this research centered on cystic fibrosis patients specifically waiting for a lung transplant, is transplant something I should be actively discussing at this stage of my condition, and would a study like this one change the timing of that conversation?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.